We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $767M
1-Year Est. Return 119.71%
This Fund
S&P 500
This Quarter Est. Return
-0.86%
1 Year Est. Return
+119.71%
3 Year Est. Return
+244.81%
5 Year Est. Return
+382.5%
10 Year Est. Return
+2,655.81%
AUM
$1.19B
AUM Growth
-$288M
Cap. Flow
+$17.4M
Cap. Flow %
1.46%
Top 10 Hldgs %
42.35%
Holding
170
New
36
Increased
27
Reduced
26
Closed
54

Top Buys

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$49M
2
LLY icon
Eli Lilly
LLY
+$41.1M
3
ABBV icon
AbbVie
ABBV
+$26.3M
4
PANW icon
Palo Alto Networks
PANW
+$13.1M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$11.8M

Top Sells

Rank Stock Value
1
MRK icon
Merck
MRK
+$60.1M
2
JNJ icon
Johnson & Johnson
JNJ
+$28.4M
3
GNRC icon
Generac Holdings
GNRC
+$14.3M
4
LPSN
LivePerson
LPSN
+$14.2M
5
AMZN icon
Amazon
AMZN
+$13.5M

Sector Composition

Rank Sector Weight
1 Healthcare 62.92%
2 Miscellaneous 16.27%
3 Technology 10.82%
4 Industrials 4.21%
5 Financials 3.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
META icon
26
Meta Platforms (Facebook)
META
$1.74T
$11.7M 0.98%
34,400
+7,400
+27% +$2.67M
CRNX
27
DELISTED
Crinetics Pharmaceuticals
CRNX
$11.5M 0.97%
548,643
-85,445
-13% -$1.79M
BMRN icon
28
BioMarin Pharmaceuticals
BMRN
$12.6B
$11.5M 0.97%
+149,017
New +$11.8M
TWLO icon
29
Twilio
TWLO
$37.8B
$11.3M 0.95%
35,500
+9,000
+34% +$3.28M
ALT icon
30
CALL
Altimmune
ALT
$630M
$11.3M 0.95%
+1,000,000
New +$12.2M
NICE icon
31
Nice
NICE
$6.17B
$10.7M 0.9%
37,786
-39,000
-51% -$10.8M
VINC
32
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
$10.6M 0.89%
32,729
+21,356
+188% +$6.23M
VTGN icon
33
VistaGen Therapeutics
VTGN
$10.4M
$10.5M 0.88%
127,498
-8,524
-6% -$741K
KRNT icon
34
Kornit Digital
KRNT
$661M
$10.4M 0.88%
72,076
-75,717
-51% -$9.99M
IMTX icon
35
Immatics
IMTX
$1.34B
$10.4M 0.87%
+800,043
New +$10.2M
INBX
36
DELISTED
Inhibrx, Inc. Common Stock
INBX
$10.3M 0.87%
310,077
+120,994
+64% +$3.68M
AUDC icon
37
AudioCodes
AUDC
$242M
$10.3M 0.87%
316,428
-68,766
-18% -$2.23M
TEVA icon
38
CALL
Teva Pharmaceutical Industries Limited
TEVA
$45.7B
$10.2M 0.86%
1,050,000
-860,000
-45% -$8.05M
ARYD
39
DELISTED
ARYA Sciences Acquisition Corp IV Class A Odinary Shares
ARYD
$10.1M 0.85%
1,000,000
+500,000
+100% +$5.05M
OMGA
40
DELISTED
Omega Therapeutics, Inc. Common Stock
OMGA
$9.95M 0.84%
+527,948
New +$10.1M
ALXO icon
41
ALX Oncology
ALXO
$241M
$9.51M 0.8%
128,706
-64,022
-33% -$4.27M
NKE icon
42
Nike
NKE
$53.9B
$9.44M 0.79%
+65,000
New +$10.6M
LENZ
43
LENZ Therapeutics
LENZ
$130M
$8.71M 0.73%
75,896
+72,331
+2,029% +$10.7M
RUN icon
44
Sunrun
RUN
$2.1B
$8.32M 0.7%
189,000
+117,000
+163% +$5.58M
ONCR
45
DELISTED
Oncorus, Inc.
ONCR
$8.23M 0.69%
880,702
-12,846
-1% -$147K
TEVA icon
46
Teva Pharmaceutical Industries Limited
TEVA
$45.7B
$8.11M 0.68%
832,878
– –
CSTE icon
47
Caesarstone
CSTE
$97.2M
$8M 0.67%
644,146
– –
ISEE
48
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$7.88M 0.66%
485,001
-14,999
-3% -$163K
ADSK icon
49
Autodesk
ADSK
$45.7B
$7.84M 0.66%
+27,500
New +$8.42M
IDYA icon
50
IDEAYA Biosciences
IDYA
$3.73B
$7.51M 0.63%
294,619
-40,175
-12% -$938K
1
2
3 4 5

Similar funds

ISWM
Independent Solutions Wealth Management Williamsville, New York $766M AUM 31.53% 1-Year Est. Return
ACP
Albar Capital Partners London, United Kingdom $767M AUM 61.96% 1-Year Est. Return
NIM
Nexus Investment Management Toronto, Ontario, Canada $767M AUM 30.97% 1-Year Est. Return
ACM
Arvin Capital Management Austin, Texas $766M AUM 36.51% 1-Year Est. Return
CBT
Crews Bank & Trust Wauchula, Florida $766M AUM 19.5% 1-Year Est. Return
SPIA
Strategic Point Investment Advisors Providence, Rhode Island $767M AUM 17.58% 1-Year Est. Return
CNB
Camden National Bank Camden, Maine $767M AUM 14.32% 1-Year Est. Return
HI
Hendershot Investments Centreville, Virginia $766M AUM 10.81% 1-Year Est. Return

Sphera Funds Management's Q3 2021 Portfolio in Review

As of Q3 2021, Sphera Funds Management held 170 positions worth $1.19B, down 19% from $1.48B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Sphera Funds Management's Q3 2021 filing shows 36 new, 27 increased, 26 reduced and 54 closed positions. Its largest new stake was Pfizer: 1,106,528 shares worth $47.6M. The largest sale was Merck, an estimated $60.1M.

By sector, the portfolio is most concentrated in Healthcare at 63% of assets, up from 55% a quarter earlier, followed by Miscellaneous and Technology.

  • Sphera Funds Management's largest Q3 2021 buy was Pfizer: 1,106,528 shares worth $47.6M.
  • Sphera Funds Management added most to Eli Lilly in Q3 2021, an estimated $41.1M increase.
  • Sphera Funds Management's biggest Q3 2021 reduction was Johnson & Johnson, cutting an estimated $28.4M.
  • Sphera Funds Management fully exited Merck in Q3 2021, selling an estimated $60.1M.
  • Sphera Funds Management's ten largest holdings make up 42% of its $1.19B portfolio in Q3 2021.
  • Sphera Funds Management opened 36 new positions and closed 54 in Q3 2021.
  • Sphera Funds Management's portfolio value fell 19% quarter-over-quarter to $1.19B.

Based on Sphera Funds Management's 13F filing for Q3 2021, filed 15 Nov 2021.